Current report No. 46/2021 – Notification about a transaction on subscription warrants of Celon Pharma S.A.
Legal basis: Article 19 section 3 of the Market Abuse Regulation (MAR) – information on transactions conducted by persons discharging managerial responsibilities.
Date: November 8, 2021, time: 9:31 a.m.
Content of the report:
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on November 5, 2021 it received a notification from the person discharging managerial responsibilities in the Company – Mr Jacek Glinka, Vice President of the Company’s Management Board – on his acquisition (under the Incentive Program for members of the Management Board) of series A registered subscription warrants entitling to acquire C series shares of the Company issued under a conditional share capital increase. The allocation of the A series subscription warrants took place on November 2, 2021.
The Company provides the notification in the attachment.